Skip to content

Effect of Branched-chain Amino Acid Supplementation on Muscle Damage

Effect of Branched-chain Amino Acid Supplementation on Muscle Damage in Recreational Athletes

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03766815
Enrollment
78
Registered
2018-12-06
Start date
2019-10-01
Completion date
2019-12-31
Last updated
2019-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle Damage

Brief summary

Seventy-eight recreational athletes who never resistance trained will be randomly assigned into three groups of twenty-six. Branched-chain amino acid will be supplemented for 18days at 0, 200 or 400 mg/body weight(kg)/day in jelly. Participants will be asked to perform elbow flexions on the 12th day of supplementation. Maximum voluntary contractions will be measured before, during and after the supplementation period to compare the effects of different doses of branched-chain amino acid has on muscle damage markers.

Detailed description

Previous studies have not been able to show consistent effects due to various reasons. The major limitations are the lack of enough data on the amount and duration of branched-chain amino acid supplementation, and the level of muscle damage for branched-chain amino acid to be effective. Based on a recent meta-analysis, it has been suggested that to be effective, branched-chain amino acid should be supplemented more than 200mg/kg/day before a low-to-moderate intensity exercise bout. Therefore, this study is designed based on the above suggestions and to compare the effect of different doses of branched-chain amino acid on muscle damage markers in healthy recreational active individuals. Three treatment groups (n=26) will be randomly assigned to be supplemented with either 200mg BCAA/kg/day (BCAA200), 400mg BCAA/kg/day (BCAA400) or placebo (fiber supplement; PL). Supplements will be provided in jelly in a single blind fashion to be ingested 1hour after each of the three main daily meals for 18days. Anthropometric measurements (body weight, lean mass, height), body temperature, ultrasound (US), strength assessment (maximal voluntary contraction, MVC), resting metabolic rate (RMR), rate of perceived exertion (RPE), delayed onset of muscle soreness (DOMS) and blood samples (duplicates; myoglobin; BCAA) will be collected before, during and after the supplementation period at different time points (see appendix for the above tables). Repeated-bout effect (RBE) on both arms will be measured 7 days after the damage inducing session.

Interventions

DIETARY_SUPPLEMENTBCAA 200mg/kg/day

BCAA supplement based on 200mg/kg/day for 18 days.

DIETARY_SUPPLEMENTPlacebo

Fiber supplement jelly for 18 days.

DIETARY_SUPPLEMENTBCAA 400mg/kg/day

BCAA supplement based on 400mg/kg/day for 18 days.

BEHAVIORALMuscle damaging exercise

Participants will be asked to perform muscle damaging elbow eccentric contraction exercise at 120% of 1RM for three sets of 15 repetitions with the dominant arm at maximal effort on a Biodex machine with a 3 minute rest period between each set.

Sponsors

Western University, Canada
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)

Masking description

Participants will not be able to distinguish branched-chain amino acid and fiber supplement by taste, color or scent as the supplements are provided in jelly.

Intervention model description

Participants will be supplemented for 18 days with either 200mg BCAA/kg/day, 400mg BCAA/kg/day or placebo (fiber supplement) in jelly in a single-blind fashion. Followed by a muscle damaging exercise and subsequent MVC and blood sample for force and metabolite measurements.

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy males and females at the age of 18-40 * Endurance trained athletes * Weekly exercise duration is less than 150minutes but more than 30 minutes

Exclusion criteria

* Individuals who cannot endure three days for not eating meat * Diabetic * Have been performing resistance trainings * Have been taking protein supplement * Have been consuming a high level of protein in the regular diet * Have been taking omega-three and vitamin E supplements * Have been taking anabolic Steroids * Have been taking regular medications * Have cardiovascular Disease * Have a history of joint & Muscle Injuries * Females with irregular Menstrual Cycle

Design outcomes

Primary

MeasureTime frameDescription
Change in maximum voluntary contraction (MVC)baseline (before supplementation) and at 1,3,24,48,72,96,120,144 hours after muscle damageParticipants will be asked to perform three repetitions of concentric elbow flexion at their maximal force (1RM) with both their dominant and non-dominant arm on an isokinetic dynamometer (Biodex).

Secondary

MeasureTime frameDescription
Change in 3-methyl-histidine10 min before muscle damaging exercise and at each of 1,3,24,48,72,96,120,144 hours after muscle damageUltra-performance liquidchromatography tandem mass spectrometry (UPLC-MS/MS) using an Acquity Ultra Performance LC system coupled to a Waters Quattro Premier XE mass spectrometer (bothWaters Corporation, Milford, MA, USA) and the Waters MassLynx Software (Version 4.1).
Changes in insulin10 min before muscle damaging exercise and at each of 1,3,24,48,72,96,120,144 hours after muscle damageBlood insulin will be measured with a standard insulin radioimmunoassay kit.
Change in muscle soreness10 min before muscle damaging exercise and at each of 1,3,24,48,72,96,120,144 hours after muscle damagePerceived muscle soreness will be determined by asking participants to stand in the anatomical position while flexing the shoulder of the exercised arm at 90degrees and fully extending the elbow. Participants will be asked to determine their forearm flexor muscles soreness with the use of a visual analogue scale (VAS) and rate from 1 being no pain and 10 being extremely painful.
Change in ultrasound images of the arm muscles10 min before muscle damaging exercise and at each of 1,3,24,48,72,96,120,144 hours after muscle damageUltrasound measurements will be used to scan the triceps brachii and the forearm flexors. A permanent marker will be used to mark the elbow joint as the origin and both the belly of the triceps and the belly of the flexor digitorum profundus as the end point so as to compare the echoic difference in both the upper and lower arms.
Change in blood myoglobin10 min before muscle damaging exercise and at each of 1,3,24,48,72,96,120,144 hours after muscle damageBlood myoglobin will be measured with Enzyme-Linked Immunosorbent Assay.
Change in body temperature20 min before muscle damaging exercise and at each of 1,3,24,48,72,96,120,144 hours after muscle damageBody temperature will be measured with an ear thermometer
Change in resting metabolic rate20 min before muscle damaging exercise and at each of 1,3,24,48,72,96,120,144 hours after muscle damageResting metabolic rate will be measured with a metabolic cart
Change in range of motion20 min before muscle damaging exercise and at each of 1,3,24,48,72,96,120,144 hours after muscle damageRange of motion of the arm will be measured by asking the participant to stand in the anatomical position while fully flexing the shoulder of the exercised arm and then extending the elbow to an angle that they do not feel any pain in the arms. A goniometer will be used to measure the angles.
Change in limb girth10 min before muscle damaging exercise and at each of 1,3,24,48,72,96,120,144 hours after muscle damageLimb girth of the upper arm (between the lateral epicondyle of the humerus and the acromion process) and the lower arm (between the lateral epicondyle of the humerus and the styloid process of the radius) will be measured with an anthropometric tape when the arm is naturally hanging down.

Countries

Canada

Contacts

Primary ContactCrystal Lee, BSc
plee263@uwo.ca519 6612111
Backup ContactArash Bandegan, PhD
abandeg@uwo.ca519 6612111

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026